• SOZO is sold based on a monthly license fee and this fee is largely paid via a reimbursement environment with private payors*/reimbursement.

• The average monthly license fee on SOZO US renewals contracts is up ~38% in Q1 FY23
• Most SOZO contracts have a stair step pricing model, in which there is an agreed price increase in years 2 and 3 for stair stepped contracts. This model locks in growth before additional unit sales
• There is currently ~$2.7m in additional ARR over the next 12 months inherent in the current SOZO contacts.
• * Payors in the health care industry are organisations which set service rates, collect payments, process claims, and pay provider claims (such as private health plans, Medicare, and Medicaid). This compares to Providers who offer health care services (such as hospitals or clinics)

• There are currently 6-sales reps and this is set to grow to 10-15, following the recent capital raise, with a longer term expectation of 25-35 sales reps

• The sales reps are supported by the CCO and a lead generation and data analytics teams
• There is also a reimbursement field support team for onboarding of private payors and providers, including building workflows, training and payor contracting support

• Additionally, Impedimed continues to offer value adds such as:

• Software and hardware enhancements
• Compliance modules to maximise patient outcomes
• EHR integration, medically meaningful and actionable data parsed to clinicians
• New indications (e.g. bodycomp, segmental, bone, etc)

• Founded* and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS)

• ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally

• Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device

• The 1 device has multiple applications (lymphoedema, heart failure, end stage renal disease, body composition etc).

• The SaaS model and product has ~90% gross margins and a churn rate less than 2%. The product is scalable, whereby users can add and move test locations without any additional software setup

* Listed on the ASX in October 2007